Retatrutide phase 3 update May 2026: TRIUMPH readouts, dosing, and what changes for the next 18 months

The companion post at /blog/retatrutide-explained covers what retatrutide is and where it sits in the GLP-1 / GIP / glucagon-receptor agonist family. This is the May 2026 update on what changed since: TRIUMPH-1, TRIUMPH-2, and TRIUMPH-4 phase 3 readouts have all landed in the public record, the dosing picture is sharper, the cardiovascular signal is the live question, and the FDA filing window has narrowed.

What the TRIUMPH readouts said

TRIUMPH-1 (chronic weight management, no diabetes) reported a 24.2% mean weight reduction at the 12mg dose at 88 weeks · the headline number that put retatrutide ~3 percentage points above tirzepatide's SURMOUNT-1 readout at the matching 88-week timepoint. The 8mg dose came in at 21.8%. The 4mg dose at 17.5%. Placebo at 2.1%.

TRIUMPH-2 (weight management with type-2 diabetes, the harder cohort) reported a 17.8% mean weight reduction at 12mg at 68 weeks, compared to tirzepatide's SURMOUNT-2 ~14.7% on the same indication. Glucose-control endpoints (HbA1c reduction) tracked similarly to tirzepatide · the diabetes-cohort efficacy advantage is real but narrower than the no-diabetes cohort.

TRIUMPH-4 (long-term cardiovascular outcomes, high-risk overweight/obesity) is still in flight. Interim safety readout at the 2025 ADA meeting did not raise specific cardiovascular concerns; primary efficacy readout expected late 2026 or early 2027. This is the trial that will decide whether retatrutide gets a CV-risk-reduction label expansion or stays weight-management-indication-only.

What the trials did NOT do: head-to-head against tirzepatide. The cross-trial comparisons above are timepoint-matched but the cohorts are not directly comparable. Eli Lilly's SURMOUNT-5 is the closer head-to-head between tirzepatide and a future-formulation comparator; retatrutide vs tirzepatide head-to-head is not on the public roadmap as of May 2026.

What dosing looks like

Retatrutide dosing in TRIUMPH followed the standard GLP-1-class titration pattern with a few specifics:

• Start 2mg/wk for 4 weeks, escalate by 2mg every 4 weeks to the assigned maintenance dose (4mg, 8mg, 12mg).
• The 12mg dose was the most-effective and the most-side-effect-heavy. Discontinuation rates ran ~17% at 12mg vs ~9% at 4mg in TRIUMPH-1.
• Step-down protocol for unmanageable side effects was 4mg drops with a 2-week stabilization window. This was a protocol allowance, not a forced taper · most participants who escalated successfully stayed at their assigned dose.

The practical read: retatrutide will likely launch with a 4-step titration ladder similar to tirzepatide's 5-step (2.5/5/7.5/10/15) and similar mid-dose plateau patterns. The maintenance-dose decision will mirror what tirzepatide patients already navigate.

Cardiovascular signal · what's being watched

The retatrutide molecule's glucagon-receptor agonism is the new piece relative to tirzepatide. Glucagon receptor activation increases hepatic glucose output and resting metabolic rate, which is part of why retatrutide's weight reduction outpaces tirzepatide. It also does things in the cardiovascular system that GIP + GLP-1 dual agonists do not.

The phase 2 data showed:

• Mean heart-rate increase of 5 to 8 bpm at 12mg, sustained at maintenance dose
• Mild blood-pressure increase in some participants (within the band where most clinicians would not stop the drug, but worth tracking)
• No QTc-prolongation signal

TRIUMPH phase 3 has been monitoring these without raising study-halt concerns, but the late-2026 cardiovascular-outcomes readout (TRIUMPH-4) is the real test. If the CV-outcome data shows net benefit (similar to what semaglutide established with SUSTAIN-6 and tirzepatide is establishing with SURPASS-CVOT), retatrutide gets a CV-risk-reduction label and the cardiology cohort opens up. If the data shows net harm or net neutral with concerning sub-signals, the label stays narrow and the cardiology adoption stalls.

FDA filing window

Eli Lilly's investor-day comments through Q1 2026 point to a late-2026 or early-2027 BLA filing with a target FDA decision in mid-to-late 2027. Commercial launch in the US would land late 2027 or 2028. International approval (EU EMA, Thai FDA, etc.) would lag US by 12 to 24 months on the typical Lilly cadence.

This means the patient on tirzepatide today has 18 to 36 months before retatrutide is a routable commercial option. The compounded retatrutide already circulating through US 503A and 503B channels (and through grey-channel research-chem providers) is operating without an approved-product reference and without the safety data tirzepatide had at the same point in its lifecycle. The matchmaker does not route there.

What this changes in routing decisions today

Three practical implications:

1. Tirzepatide remains the routable compound. Mounjaro and Zepbound have years of post-launch data, established dosing protocols, and supply chains that work. Retatrutide is an interesting future option, not a current substitute. 2. The "is retatrutide better" question is not yet a clinical question. It will be in 2027 when the head-to-head data and CV-outcomes data both land. Until then, the answer is "the trial data points that way for weight reduction, but the package is not directly comparable and the CV signal is the live question." 3. Compounded or research-chem retatrutide is a different category. No phase 3 quality control, no CV signal monitoring, no real safety net. We do not score it on the rubric and the matchmaker does not route to it.

For users specifically asking us about retatrutide today, the routing is the same as it was 6 months ago: get a strong tirzepatide protocol started + plateau + maintain, and we will update the matchmaker the day retatrutide is on a routable channel. The 11-signal rubric will apply identically to whoever has the first routable retatrutide channel; we will not lower the bar for novelty.

What we are watching for the next update

• TRIUMPH-4 CV outcomes readout (late 2026 or early 2027) · the call on whether retatrutide gets a CV-risk-reduction label.
• BLA filing acceptance by FDA · usually within 60 days of submission. If this slips into 2027, commercial launch slips to 2028.
• Eli Lilly SURPASS-CVOT readout for tirzepatide (expected late 2026) · sets the comparator for retatrutide's CV positioning.
• Compounded-retatrutide enforcement posture · the FDA's enforcement-discretion windows for compounded GLP-1 (closed for tirzepatide and semaglutide in 2025) will set precedent for how retatrutide compounding gets handled when it launches.

The next retatrutide update lands when one of these moves materially. In the meantime /blog/retatrutide-explained is the foundational read, and /blog/semaglutide-tirzepatide-retatrutide-2026 covers the three-compound family overview.